CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

In Boston on June 22, 2026, CervoMed Inc. (NASDAQ: CRVO), a biotech company focusing on age-related brain disorders, revealed the completion of a registered direct offering under Nasdaq rules. The offering involved the sale and purchase of 2,500,000 common stock shares at $4.00 per share. This move marks a significant step for CervoMed in its clinical-stage development of treatments for age-related brain conditions.